

PROVIDER BULLETIN **No. 14-18**

DATE: April 9, 2014

TO: All Medicaid Providers

FROM: Vivianne M. Chaumont, Director 
Division of Medicaid & Long-Term Care

BY: Lisa deVries R.P., Pharmacy Consultant
Division of Medicaid & Long-Term Care

RE: Coverage of Hydroxyprogesterone Caproate

Please Share This Information with Administrative, Clinical and Billing Staff

This provider bulletin replaces Provider Bulletin No. 13-31 (April 30, 2013).

This bulletin applies to services provided to clients enrolled in fee-for-service Medicaid.

Effective immediately, Nebraska Medicaid will provide benefit coverage for both Makena® and compounded hydroxyprogesterone caproate without prior authorization.

The criteria for benefit consideration are as follows:

1. The pregnancy must be a singleton pregnancy; and
2. The client must have had a previous pre-term delivery (i.e., a spontaneous birth before 36 weeks gestation, history of preterm rupture of membranes or incompetent cervix); and
3. No more than 20 doses (16 weeks gestation to 36 weeks gestation) should be administered.

Other risk factors for preterm delivery do not qualify for coverage. While prior authorization is not required, prescribers must maintain documentation in each client's medical record for review by DHHS Medicaid and Long-Term Care.

Required medical record information includes:

1. Documentation of previous spontaneous singleton preterm birth
 - a) Date of pregnancy
 - b) Gestational age at birth
 - c) Confirm previous preterm birth was:
 - i) Spontaneous

- ii) Singleton
- 2. Documentation of current pregnancy
 - a) Estimated date of current of conception
 - b) Current gestational age including weeks, days
 - c) Current pregnancy is singleton
 - d) Therapy initiation date which must be between \geq 16 weeks, 0 days gestational age and \leq 20 weeks, 6 days gestational age
 - e) Date of last prescribed dose which must be \leq 36 weeks, 6 days gestational age

Please continue to use the following codes for claims submissions:

- J1725 – Makena®
- J1725 TH – compounded form of hydroxyprogesterone caproate

Please email questions regarding this provider bulletin to:

DHHS.MLTCphysicalhealth@Nebraska.gov